Publication | Closed Access

Phase II Activity of the HSP90 Inhibitor AUY922 in Patients with Alk-Rearranged (ALK+) or Egfr-Mutated Advanced Non-Small Cell Lung Cancer (NSCLC)

Phase Ii ActivityMedicinePathologyHsp90 Inhibitor Auy922Bronchial NeoplasmCancer TreatmentCancer GeneticsOncologyRadiation OncologyLung Cancer